Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
Earnings Data
Report Date
Mar 04, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.41Last Year’s EPS
-1.26Same Quarter Last Year
Strong Buy
Based on 17 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards the approval and commercial readiness of aficamten, supported by strong clinical trial results and a solid financial position. However, increased net loss and pending regulatory approvals present challenges.Company Guidance
Progress Towards FDA Approval of Aficamten
Cytokinetics made significant progress in preparing for the potential FDA approval of aficamten for patients with oHCM, with constructive engagements with the FDA and completion of key commercial launch readiness activities.
MAPLE-HCM Trial Success
The MAPLE-HCM trial demonstrated the superiority of aficamten over metoprolol in patients with oHCM, showing significant improvements in exercise capacity and challenging the use of beta blockers as the standard-of-care therapy.
Strong Financial Position
Cytokinetics has a strong balance sheet with approximately $1.25 billion in cash and investments, bolstered by a convertible note offering that provides additional capital and financial flexibility.
European and Global Expansion Plans
Preparations for potential commercial launch of aficamten in the EU and coordination with Sanofi for potential approval in China are well underway, with expected EMA approval in the first half of 2026.
CYTK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CYTK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | $59.19 | $60.30 | +1.88% |
Aug 07, 2025 | $35.25 | $34.11 | -3.23% |
May 06, 2025 | $33.97 | $33.04 | -2.74% |
Feb 27, 2025 | $47.45 | $46.00 | -3.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytokinetics (CYTK) report earnings?
Cytokinetics (CYTK) is schdueled to report earning on Mar 04, 2026, After Close (Confirmed).
What is Cytokinetics (CYTK) earnings time?
Cytokinetics (CYTK) earnings time is at Mar 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CYTK EPS forecast?
CYTK EPS forecast for the fiscal quarter 2025 (Q4) is -1.41.